E75.27
Pelizaeus-Merzbacher disease
Clinical Classification Guidelines
Medical Intelligence & Overview
Pelizaeus-Merzbacher disease is a rare genetic disorder that affects the central nervous system. It is characterized by the abnormal development or loss of myelin, the protective covering that surrounds nerve fibers in the brain and spinal cord. This degradation disrupts the normal transmission of nerve signals, leading to various neurological symptoms. The condition is typically diagnosed in infancy or early childhood and requires ongoing management to support affected individuals.
Causes & Symptoms
Clinical Causes: Mutations in the PLP1 gene, which provides instructions for making a protein essential for myelin formation. Genetic inheritance, often passed down in an X-linked pattern, primarily affecting males. No known environmental causes have been linked to the development of this disease.
Key Symptoms: Muscle stiffness or spasticity Poor muscle tone (hypotonia) Nystagmus, which causes involuntary eye movements Delayed motor development, such as sitting or walking later than usual Difficulty with coordination and balance Intellectual disabilities or learning difficulties Delayed speech development Breathing problems in severe cases Seizures, though less common
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of clinical assessment, family history, and specialized tests. These may include genetic testing to identify mutations in the PLP1 gene and MRI scans that show abnormal myelination patterns in the brain. Early detection is essential for managing symptoms effectively and providing timely support to affected children.
Treatment Protocols: There is currently no cure for Pelizaeus-Merzbacher disease. Management primarily focuses on alleviating symptoms and improving quality of life. Treatment approaches include physical therapy to enhance motor skills, speech therapy for communication challenges, and supportive care for breathing and other complications. Regular medical follow-up is important to monitor the progression of the disease and address specific needs as they arise.
Clinical Advice & FAQs
Billing Guidance
Is E75.27 a billable ICD-10 code?
Yes, E75.27 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E75.27?
Clinical documentation must specify the nature of Pelizaeus-Merzbacher disease and any associated comorbidities for accurate reporting.
Cite this Clinical Reference